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Introduction. 'e Geriatric Depression Scale (GDS) is commonly used to assess depressive symptoms, but its psychometric
properties have never been examined in Italian people with Parkinson’s disease (PD). 'e aim of this study was to study the
reliability and validity of the Italian version of the GDS in a sample of PD patients. Methods. 'e GDS was administered to 74
patients with PD in order to study its internal consistency, test-retest reliability, construct, and discriminant validity. Results. 'e
internal consistency of GDS was excellent (α� 0.903), as well as the test-retest reliability (ICC� 0.941 [95% CI: 0.886–0.970]). GDS
showed a strong correlation with instruments related to the depression (ρ� 0.880) in PD (ρ� 0.712) and a weak correlation with
generic measurement instruments (−0.320< ρ<−0.217). An area under the curve of 0.892 (95% CI 0.809–0.975) indicated
a moderate capability to discriminate depressed patients to nondepressed patient, with a cutoff value between 15 and 16 points
that predicts depression (sensitivity� 87%; specificity� 82%).Conclusion.'eGDS is a reliable and valid tool in a sample of Italian
PD subjects; this scale can be used in clinical and research contexts.
1. Introduction
Parkinson disease (PD) is characterized by motor and
nonmotor symptoms. Bradykinesia, tremor at rest, and ri-
gidity are the cardinal motor manifestations of PD [1].
Nonmotor symptoms include gastrointestinal dysfunctions,
sleep disorders, cognitive disorders, and neuropsychiatric
disturbances. Depression has been found to be more fre-
quent in PD patients than in age-matched healthy controls
or in patients with other chronic medical conditions [2, 3].
For example, major depressionmay be found in up to 20% of
PD patients [4]. To measure the level of depression, it is
crucial that clinicians and researchers have access to reliable
and valid instruments. A recent systematic review about
depression tools in PD patients recommended the use of the
Hamilton Depression Inventory as a rating scale, which
takes into consideration the judgment of the clinician or the
caregiver, and the Geriatric Depression Scale (GDS), that
considers the patient’s point of view, for the screening and
measurement of the degree of perceived depression in pa-
tients with PD [5].
'e GDS [6], composed by 30 items, was developed to
evaluate the level of depressive symptoms over the past week.
It was transculturally adapted in several languages [7–9], and
it has proven to be reliable and valid in subjects with de-
mentia [10–13], stroke [14–17], rheumatoid arthritis [18],
and psychiatric disorders [19, 20]. In PD, several studies
showed that GDS has good psychometric properties, a high
internal consistency (Cronbach’s alpha� 0.92) [21], an ex-
cellent test-retest reliability (intraclass correlation coef-
ficient� 0.89 [95% CI 0.83–0.93]), and a minimal detectable
change of 5.4 points [22]. Taking into account the validity,
the GDS showed good correlations with the Beck Depression
Inventory (rs � 0.62, p< 0.05) and with mood related items
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of the Unified Parkinson’s Disease Rating Scale
(rs � 0.38, p< 0.05) [23], and moderate correlations with
the 17-item Hamilton Depression Rating Scale
(r � 0.54, p< 0.001) [24]. Recently, the GDS was used in an
Italian sample of geriatric patients, and this study confirmed
the good psychometric properties of GDS [25]. As the
measurement properties of an instrument are affected by the
disease investigated and by the contextual factors, for a re-
liable and valid use of the instrument in Italian subjects, the
GDS should be validated also in the target population to
which the questionnaire will be administered. No study has
assessed the psychometric properties of GDS in Italian
patients with PD.'erefore, the aim of this study is to assess
the reliability and the validity of the GDS in a sample of
Italian PD patients, using the Classical 'eory Test.
2. Methods
2.1. Subjects. Seventy-four (older than 18 years) patients
with clinically diagnosed PD were consecutively recruited
through a convenience sample in the Rehabilitation Unit of
San Giovanni Battista Hospital, Polyclinic Italia, and in the
Department of Neurosciences, Sapienza University of Rome.
Patients with cognitive impairment (Mini-Mental State
Examination score <23 points) and problems with reading
and understanding the Italian language were excluded. All
subjects gave their informed consent [26, 27] to participate
in the study, and the research was conducted according to
the principles of Declaration of Helsinki.
2.2. Outcome Measures
2.2.1. Geriatric Depression Scale. 'is scale assesses the
depressive symptoms [6]. 'e version used in this study was
composed by 30 items that investigated different aspects of
the depression over the last week. Each item is rated by
a dichotomous score (yes� 1; no� 0), and some items (Item
numbers 1, 5, 7, 9, 15, 19, 21, 27, 29, and 30) presented
a reverse score (yes� 0; no� 1). 'e total score is given
adding the item scores, and it ranged from 0 (no depression)
to 30 (maximum depression) points.'e Italian version used
in this study demonstrated to be reliable and valid [25].
2.2.2. Hospital Anxiety and Depression Scale. 'is scale
measures the level of depression and anxiety [28]. It is
composed by 14 items divided in two subscales: 7 items
investigate depressive symptoms, and the other 7 measure
anxious symptoms. Subjects respond to each item on four-
level ordinal score (0� no symptoms; 3�maximum
symptoms); therefore, the total scores may vary between
0 and 21 points for each subscale. 'e Italian version of the
scale was used in this study [29].
2.2.3. Parkinson Disease Questionnaire. 'is questionnaire
assesses the impact of parkinsonian symptoms in the life of
these patients in the past month [30]. It contains 39 items
that examine 8 domains through separately scored subscales:
mobility (10 items), activities of daily living (6 items),
emotional well-being (6 items), stigma (4 items), social
support (3 items), cognition (4 items), communication (4
items), and bodily discomfort (3 items). A 5-point level score
is attributed to each item (0� never; 1� occasionally/rarely;
2� sometimes; 3� often; 4� always). A total score ranging
from 0 (indicating best health status) to 100 (indicating
worst health status) was calculated by summing the score of
each item, both for the 8 subscores and for the total score.
'e Italian version used in this study was recently evaluated
[31] and revealed good psychometric properties.
2.2.4. Short Form 36-Health Survey Questionnaire (SF-36).
'is is a 36-item questionnaire measuring the patient’s
health status in the past four weeks [32]. 'e total score
ranges from 0 to 100 with higher scores indicating a better
condition. 'e Italian version is considered to be a valid and
reliable tool [33].
2.2.5. Barthel Index. 'is well-known test measures the
disability on the ADLs [34]. It is composed of 10 items
including feeding, bathing, grooming, dressing, bowel and
bladder control, toilet use, transfers (bed to chair and back),
mobility, and stairs climbing. 'ree ordinal level scores are
attributed to each item (0, 5, or 10; 15 points for items
regarding transfers and mobility) to assess whether the
patient can perform the various activities independently,
with assistance or whether they are totally dependent from
others. 'e total score is generated summing each score, and
it varies from 0 (total dependence) to 100 (total in-
dependence). 'e Italian version was administered in this
study [35, 36].
2.3. Procedures. Four clinicians (three occupational thera-
pists and one physical therapist) screened all patients for
their recruitment. Once enrolled, these clinicians collected
demographic and clinical variables and administered the
outcome measure to all patients. In order to study the test-
retest reliability, the GDS was readministered after seven
days. To assess the discriminant validity, a physician di-
agnosed the depression in this sample. According to DSM-5,
patients were diagnosed with depression if they had at least
five depressive symptoms including “depressed mood” and
“loss of interest or pleasure” for at least two weeks [37].
2.4. Statistical Analysis. Descriptive statistics was used to
analyze the sample characteristics; in particular, mean±
standard deviation (SD), median with 25th and 75th per-
centiles, and frequency with percentage were calculated for
intervallic, ordinal, and categorical data, respectively.
'e reliability of GDS was assessed in terms of internal
consistency and test-retest reliability. Internal consistency
was determined calculating Cronbach’s alpha [38]: for values
closer to 1, the internal consistency is higher. Alpha was
considered excellent if >0.9, good if >0.8, and acceptable if>0.7 [39]. Test-retest reliability was calculated by the
intraclass correlation coefficient (ICC) with a 95% confident
interval (CI). ICC values greater than 0.75 are a minimum
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requirement to use the instrument in group measurements
[40]; ICC values greater than 0.90 are considered essential
for the use of the instrument in individual measurements
[41].
'e construct validity of the GDS was studied calculating
the Pearson correlation coefficient (ρ) when comparing the
GDSwith the other administered instruments.'e following
ranges were considered in order to interpret the results:
ρ> 0.70� strong correlation, 0.50< ρ< 0.70�moderate
correlation, and e ρ< 0.50�weak correlation [42].
In order to study the discriminant validity, the receiving
operating characteristic (ROC) curve was created, and the area
under the curve (AUC) was calculated. 'e closer the AUC
value is to 1.0, the greater the instrument’s ability to distin-
guish depressed and nondepressed patients. An AUC higher
than 0.75 confers to the tool a moderate discriminative val-
idity; while an excellent one is demonstrated by a value ≥0.90.
For all statistical analyses, the α value was set at 0.05, and
SPSS statistical software program, version 18.0 for Windows
(SPSS Inc., Chicago, IL, USA), was used.
3. Results
3.1. Sample Characteristics. Seventy-four patients (44 males;
30 females) with PD were included in this study. 'e de-
mographic and clinical characteristics of the patients studied
are reported in Table 1.
3.2. Internal Consistency. 'e internal consistency for the
total GDS score was excellent (α� 0.903).
3.3. Test-Retest Reliability. Test-retest reliability was assessed
in a subsample of 35 patients. Excellent reliability was ob-
served for the GDS total score (ICC� 0.941 [95% CI:
0.886–0.970]).
3.4. Validity. Pearson’s correlation coefficient values are
reported in Table 2. Taking into account the comparisons
between GDS and the other instrument related to depression
(HADS) and PD (PDQ-39), Pearson coefficient ranged
between 0.712 and 0.880, indicating a strong correlation. On
the other hand, regarding the comparisons between GDS
and generic measurement instrument (Barthel Index and
SF-36), the correlation coefficient varied from −0.320 to−0.217, showing a weak correlation.
Regarding the discriminant validity, the AUC showed
a value of 0.892 (95% CI 0.809–0.975), indicating a moderate
capability to discriminate depressed patients to non-
depressed patient. 'e score with the best sensibility and
specificity that predicts depression is between 15 and 16
(sensitivity� 87%; specificity� 82%) (Figure 1).
4. Discussion
'e use of a reliable and valid instrument is essential in
clinical practice and whenmeasuring specific outcomes [43].
Several questionnaires are available tomeasure depression in
patients with PD [5]. 'e psychometric properties of GDS
have been extensively studied in different pathologies and in
different settings. To our knowledge, however, no study
assessed the psychometric properties of GDS in Italian
Table 1: Main demographic and clinical characteristics of the
sample (N � 74).
Variables Values
Age (years)a 66.9± 9.7
Genderb
(i) Male 44 (59.5%)
(ii) Female 30 (40.5%)
Depressionb
(i) Presence 23 (31.1%)
(ii) Absence 51 (68.9%)
Medications prescribed to depressed subjects
(N�23)b
(i) Antidepressant 11 (47.8%)
(ii) Anxiolytic 10 (43.5%)
(iii) No medications 2 (8.7%)
Educational levelb
(i) Primary 9 (12.2%)
(ii) Secondary 17 (23%)
(iii) High school 33 (44.6%)
(iv) Degree 13 (17.6%)
(v) Not reported 3 (4.1%)
Employmentb
(i) Employed 13 (17.6%)
(ii) Not employed 4 (5.4%)
(iii) Retired 57 (77%)
Marital statusb
(i) Married 56 (75.6%)
(ii) Unmarried 17 (23%)
(iii) Not reported 1 (1.4%)
Time since PD diagnosis (years)a 7.8± 5.6
Hoehn and Yahr stagec 3 (2; 3)
Settingb
(i) Department 20 (27%)
(ii) Ambulatory 53 (71.6%)
(iii) Day-hospital 1 (1.4%)
MMSE scorec 29 (27.25; 30)
HADS-A scorec 7 (4; 10)
HADS-D scorec 7 (4; 10)
HADS total scorec 15 (10; 20)
GDS total scorec 13 (6; 19)
PDQ-39 subscale scorec
(i) Mobility 17.5 (7.5;25.75)
(ii) Activities of daily living 10 (4; 15.75)
(iii) Emotional well-being 9 (5; 14)
(iv) Stigma 4 (2; 8)
(v) Social support 1 (0; 3.75)
(vi) Cognition 5 (2; 8)
(vii) Communication 3 (1.25; 6)
(viii) Bodily discomfort 4 (2; 7)
PDQ-39 total scorec 59 (31.25; 76)
SF-36c 95 (86.25; 102)
Barthel Indexc 85 (75; 95)
Data are expressed as amean± standard deviation, bfrequency with per-
centage, or cmedian with 25th and 75th percentiles. MMSE: Mini-Mental
State Examination; HADS-A: Hospital Anxiety and Depression Scale of
Anxiety; HADS-D: Hospital Anxiety and Depression Scale of Depression;
GDS: Geriatric Depression Scale; PDQ-39: Parkinson’s Disease Ques-
tionnaire; SF-36: Short Form 36-Health Survey Questionnaire.
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patients with PD. Studying the measurement properties in
the context in which the instrument will be administered is
crucial because these properties can be influenced by various
contextual, social, and environmental factors [44]. 'e re-
sults of our study show that GDS is a reliable and valid
instrument in Italian patients with PD.
'e internal consistency assessed by calculating Cron-
bach’s alpha (equal to 0.903) was excellent. 'e results
obtained in the PD patients we studied are similar to those
obtained in patients with different clinical conditions. For
example, Cronbach’s alpha was found to be 0.876 in a study
on 294 geriatric patients [45] and 0.90 in 888 depressed and
nondepressed elderly subjects [46].
We demonstrated an excellent test-retest reliability of
the questionnaire (ICC� 0.941). 'e results obtained in our
sample of PD patients are similar to those found in a cohort
of 75 Chinese subjects with PD (ICC� 0.89 [95% CI
0.83–0.93]) [22].
'e construct validity was investigated through the
correlations between the GDS and other validated ques-
tionnaires. In particular, a strong construct validity was
obtained through correlations with HADS (both with
anxiety and depression) and PDQ-39. On the other hand,
a weak correlation was found when the GDS was compared
with the Barthel Index and the SF-36. 'e strong
correlations between GDS and HADS can be explained
because these two scales intend to measure the same vari-
able, that is, the depression; these results are in line with
previous studies that obtained similar correlations with
questionnaires related to depression—Beck Depression In-
ventory (rs � 0.62, p< 0.05) [23] and Hamilton Depression
Rating Scale at 17 items (r � 0.54, p< 0.001) [24]. Con-
versely, the low correlation found with SF-36 and Barthel
Index may be explained because both the Barthel Index and
the SF-36 are generic instruments.
Finally, the discriminating validity was studied through
the ROC curve in order to identify the best sensitivity and
specificity of the cutoff value that can distinguish depressed
and nondepressed patients. 'e cutoff value of 15–16 points
showed a sensitivity of 87% and a specificity of 82%.
Comparing our results with those obtained in other studies
is not easy considering the different patient populations and
the different settings; for example, the study by McDonald
et al. showed a cutoff value of 9–10 points [24] and the study
by Ertan et al. [7] a cutoff value of 13–14.
'is study presents limitations that need to be taken into
account. 'e design of the study did not allow the assess-
ment of some fundamental psychometric properties such as
content validity and responsiveness.
In conclusion, this study shows that GDS can be used in
clinical practice as a valid measurement instrument in order
to quantify depression in patients with PD.
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